What question did this study set out to answer?

To examine the prevalence of comorbidities and the incidence of clinical events in patients with pulmonary arterial hypertension.

April 10, 2026Open Access

Comorbidities and Events of Clinical Interest in Patients with Pulmonary Arterial Hypertension (PAH): Analysis of Real‐World Data

Key Points

To examine the prevalence of comorbidities and the incidence of clinical events in patients with pulmonary arterial hypertension.
Retrospective analysis of a linked claims-EHR cohort in the U.S.
Included 16,749 patients with pulmonary arterial hypertension.
Identified prevalence of hypertension, heart failure, diabetes, and chronic kidney disease.
Calculated incidence rates for thrombocytopenia and major bleeding.
Hypertension, heart failure, diabetes, and chronic kidney disease were common comorbidities.
Incidence rates for thrombocytopenia and major bleeding were 8.2 and 7.3 per 100 person-years, respectively.

Abstract

ABSTRACT Pulmonary arterial hypertension (PAH) patients frequently present with cardiometabolic comorbidities and experience substantial hematologic and cardiovascular events. In a retrospective U.S. linked claims‐EHR cohort ( n = 16,749), hypertension, heart failure, diabetes, and CKD were common. Incidence rates (per 100 person‐years) for thrombocytopenia and major bleeding were 8.2 and 7.3, respectively.

Comorbidities and Events of Clinical Interest in Patients with Pulmonary Arterial Hypertension (PAH): Analysis of Real‐World Data

Key Points

Abstract

Cite This Study